No Data
Henlius Biotech Launches Phase 2 Liver Cancer Trial
Henlius (02696): The phase 2 clinical study of HLX53, in combination with Hansiway and Hanbetaine, for the treatment of locally advanced or metastatic liver cancer, has completed the first patient dosing in China.
Henlius (02696) released an announcement stating that recently, HLX53 (an Fc fusion protein that targets TIGIT) (H...
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
China Securities Co., Ltd. expects that the "expanding domestic demand" trade will gradually grow, covering cyclical and growth stocks.
China Securities Co.,Ltd. released a research report stating that it is expected that the 'expanding domestic demand' trade will gradually grow, covering both cyclical and growth stocks.
Henlius Biotech Merger Delay Announcement
Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer
No Data
